Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
10 min read
Pityriasis lichenoides et varioliformis acuta Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Pityriasis lichenoides et varioliformis acuta strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with.
Latest Hotspot
10 min read
Lymphomatoid papulosis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Lymphomatoid papulosis strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Latest Hotspot
10 min read
Erythema nodosum Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
Explore the 2026 Erythema nodosum indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
10 min read
Fixed drug eruption Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
Explore the 2026 Fixed drug eruption indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
10 min read
Stevens-Johnson syndrome Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Stevens-Johnson syndrome strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with PatSnap MCP evidence.
Latest Hotspot
10 min read
Macular amyloidosis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
Explore the 2026 Macular amyloidosis indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
10 min read
Erythema multiforme Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
Explore the 2026 Erythema multiforme indication strategy: epidemiology, unmet need, target biology, clinical competition and deal signals using PatSnap MCP evidence.
Latest Hotspot
10 min read
Primary localized cutaneous nodular amyloidosis Indication Strategy Report 2026: Epidemiology, Targets, Trials and Deals
7 August 2026
2026 Primary localized cutaneous nodular amyloidosis strategy covering epidemiology, unmet need, target biology, clinical competition and deal signals, built with.
8 min read
KSP-0914 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
KSP-0914: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
IMSB-301 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
IMSB-301: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
NVP-1603 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
NVP-1603: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.
8 min read
TQB3019 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
7 August 2026
TQB3019: Not disclosed. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.